Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00000392
First received: January 17, 2000
Last updated: November 14, 2013
Last verified: October 2013
  Purpose

To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals.

Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients.

Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.


Condition Intervention Phase
HIV Infections
Cognition Disorders
Drug: Peptide T
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment: 100
Study Start Date: January 2000
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have:

    1. Cognitive dysfunction on neuropsychological testing.
    2. HIV antibody positivity.
    3. Expected survival of 6 months.
    4. EITHER no use of an antiretroviral within the past 4 weeks OR use of approved regimens of AZT, ddI, or ddC.
    5. Medically stable EKG and urinalysis.
    6. Given informed, written consent to participate.
  • Allowed:

    1. Inhaled aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis, dapsone, cotrimoxazole, topical antifungal agents, nystatin or ketoconazole, acyclovir.
    2. Amitriptyline (up to 50 mg/day) or an equivalent dose of another antidepressant for relief of peripheral neuropathy that is expected to remain unchanged throughout the first 6 months of the study.
  • Abstinence or agree to use barrier methods of birth control / contraception during the study
  • Negative pregnancy test within 30 days of study entry
  • Bilirubin <= 3
  • CD4 (Must be <= 500 cells/mm3 if patient is without non-cognitive HIV-related symptoms. CD4 count > 500 cells/mm3 allowed if patient has other (non-cognitive) HIV-related symptoms. ( 0 - 100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 plus.)
  • Creatinine <= 1.5 mg/dl
  • Granulocytes >= 750
  • Hemoglobin > 8 g/dl (No more than two transfusions per month permitted.)
  • Other Lab Values Prothrombin time > 70 percent of control.
  • Platelet Count >= 75000 /mm3
  • SGOT(AST) < 5 x ULN (ULN = upper limit of normal).

Exclusion Criteria:

  • Patients with the following are excluded:

    1. History of mental retardation or learning disability.
    2. Evidence of current DSM-III-R Axis I disorder within 3 months prior to study entry or past history of psychotic disorder or bipolar mania.
    3. History of neurologic disorder not secondary to HIV infection (e.g., head trauma requiring medical observation or hospitalization, seizure disorder).
  • Patients with the following symptoms or conditions are excluded:

    1. Kaposi's sarcoma or other malignancy likely to require chemotherapy during the first 6 months of the study.
    2. Serious underlying medical problems that may complicate interpretation of the treatment results, including unstable diabetes mellitus, severe arteriosclerotic heart disease, uncontrolled hypertension, or hepatic or renal failure.
    3. Non-HIV related condition that is likely to interfere with interpretation of neuropsychologic test results.
    4. Inability to participate in neuropsychologic testing or unable to comply with intranasal study medication administration.
  • Excluded within 4 weeks prior to study entry:

    1. Antiretrovirals except as allowed in the Patient Inclusion Criteria.
    2. Psychoactive agents (e.g., benzodiazepines, antidepressants, antipsychotics, amphetamines)

Excluded within 8 weeks prior to study entry:

Long-acting psychoactive agents (e.g., Prozac).

  • Active alcohol abuse in the past 3 months, or abuse judged by the investigators as likely to interfere with the analyses of neuropsychologic function. Abuse of cocaine, marijuana, heroin or other opiates (including methadone), barbiturates, amphetamines or other substances within the past 3 months, judged by the investigators as likely to interfere with the analyses of neuropsychologic tests.
  • Positive pregnancy test within 30 days of study entry
  • No abstinence or no agreement to use barrier methods of birth control / contraception during the study
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000392

Locations
United States, California
Los Angeles County - USC Med Ctr
Los Angeles, California, United States, 90033
UCSD
San Diego, California, United States, 92103
United States, Florida
Univ of Miami School of Medicine
Miami, Florida, United States, 33136
Sponsors and Collaborators
  More Information

No publications provided

Responsible Party: National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier: NCT00000392     History of Changes
Other Study ID Numbers: N01 MH00013, N01MH20004, N01MH20007
Study First Received: January 17, 2000
Last Updated: November 14, 2013
Health Authority: United States: Federal Government

Keywords provided by National Institute of Mental Health (NIMH):
Acquired Immunodeficiency Syndrome
AIDS-Related Complex

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Cognition Disorders
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on April 23, 2014